In addition, tumor PD-L1 upregulation occurs in response to IFNγ release by effector immune cells, leading to subsequent immune suppression, a process known as adaptive immune resistance, where tumor cells protect themselves from immune attack (108). Here, IFNG is linked to neoplasm.